Drug maker Celgene Corp.'s (CELG) board authorized the repurchase of up to an additional $3.0 billion of its common stock. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by management and in accordance with applicable requirements of the Securities and Exchange Commission.
Year-to-date, Celgene has bought back nearly $1.8 billion of its common stock and has exhausted the earlier $2.5 billion stock buyback authorization. Celgene has repurchased around $6.5 billion of its common stock over the last 4 years.
For comments and feedback: editorial@rttnews.com